Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development
- PMID: 30631758
- PMCID: PMC6304615
- DOI: 10.1155/2018/4601420
Entamoeba Histolytica: Updates in Clinical Manifestation, Pathogenesis, and Vaccine Development
Abstract
Entamoeba histolytica is the responsible parasite of amoebiasis and remains one of the top three parasitic causes of mortality worldwide. With increased travel and emigration to developed countries, infection is becoming more common in nonendemic areas. Although the majority of individuals infected with E. histolytica remain asymptomatic, some present with amoebic colitis and disseminated disease. As more is learned about its pathogenesis and the host's immune response, the potential for developing a vaccine holds promise. This narrative review outlines the current knowledge regarding E. histolytica and E. dispar and insight in the development of a vaccine.
References
-
- United States Centers for Disease Control and Prevention. Amebiasis—biology. http://www.cdc.gov/parasites/amebiasis/biology.html.
-
- Bercu T. E., Petri W., Behm J. W. Amebic colitis: new insights into pathogenesis and treatment. Current Gastroenterology Reports. 2007:429–433. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
